News

The new drug application was filed after a 209 randomized patient, placebo-controlled clinical trial was conducted, which subsequently met the primary endpoints in all three dosing arms. Akorn

Terms of the agreement include a cash settlement of JPY30.4 billion (approximately $250 million) to be paid by Lion to Bristol-Myers Squibb. Bristol-Myers Squibb is selling the rights

The company said that the modified intent-to-treat clinical cure rate for cethromycin was 82.9%, compared to 88.5% for Biaxin. Under this analysis, the study met the endpoint of

Angiox is an anticoagulant used in patients undergoing percutaneous coronary interventions (PCI), commonly referred to as angioplasty. The product is approved in 26 European markets. The Medicines Company

The US agency said the company had not demonstrated the efficacy of the painkiller, because statistical analysis of data from the trials did not address missing data from

Genmab is now planning to expand the antibody’s development in cancer, specifically the existing non-cutaneous T-cell lymphoma and cutaneous T-cell lymphoma clinical programs, and to create a unibody

The trial is expected to enroll approximately 800 patients at around 100 clinical centers in North America and Europe and is the final phase III trial in NicOx’s

Connelly is a partner in the Foley & Lardner LLP law firm, where he has served as founding chairman of its Health Law Practice. He was a director

Under the terms of the agreement, California-based Dynavax receives a non-exclusive license under Coley’s immunostimulatory oligonucleotide patent estate for the commercialization of Hepsilav. In addition to the initial